JNJ-17299425
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Traumatic Brain Injury
Conditions
Traumatic Brain Injury
Trial Timeline
Aug 1, 2007 → Aug 1, 2008
NCT ID
NCT01814982About JNJ-17299425
JNJ-17299425 is a phase 2 stage product being developed by Johnson & Johnson for Traumatic Brain Injury. The current trial status is terminated. This product is registered under clinical trial identifier NCT01814982. Target conditions include Traumatic Brain Injury.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01814982 | Phase 2 | Terminated |
Competing Products
20 competing products in Traumatic Brain Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product | Sun Pharmaceutical | Phase 1 | 33 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 52 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Adjunctive asenapine | Merck | Approved | 85 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Alendronate | Merck | Approved | 85 |
| Iloperidone + Placebo | Novartis | Phase 2 | 52 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| Growth Hormone | Novo Nordisk | Phase 2 | 51 |